Lesion-by-lesion analysis revealed significant differences in [<sup>18</sup>F]-FTT uptake by primary tumor type (P < 0.001) and higher uptake in lesions with BRCA2 mutations (n = 65) than in lesions with other genetic mutations (n = 26) (6.7 vs. 5.5, P = 0.03). This evidence concerns the gene BRCA2 and neoplasm.